Trial reportBMC cancer2017
A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer.
Trial report in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00699881 (Phase II Study of Cetuximab), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of Cetuximab (Erbitux®) in Combination With Modified FOLFIRI in Patients With Advanced Gastric Cancer Who Failed to First-line Chemotherapy
Who cites it
8 citing papers in PubMed.
- First-line maintenance strategies and later-line options in patients with advanced gastroesophageal adenocarcinoma.Therapeutic advances in medical oncology · 2025Review
- Potential diagnostic, prognostic, and predictive biomarkers of gastric cancer.Health science reports · 2024Article
- Issues of origin, morphology and clinical significance of tumor microvessels in gastric cancer.World journal of gastroenterology · 2021Review
- Review
- Gastric cancer with repeated metastasis in the colonic lumen: a case report and multi-surgical experience.The Journal of international medical research · 2021Article
- Significant function and research progress of biomarkers in gastric cancer.Oncology letters · 2020Review
- Targeting EGFR in Esophagogastric Cancer.Frontiers in oncology · 2020Review
- Effects of Jinlongshe granules on gastric precancerous lesions in rats and its mechanism.International journal of clinical and experimental pathology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the efficacy of cetuximab combined with modified FOLFIRI (mFOLFIRI) as a second-line treatment in metastatic gastric cancer patients and to identify potential biomarkers of clinical outcomes.
methodsAll 61 patients received an initial intravenous (IV) dose of cetuximab (400 mg/m
resultsThe response rate (RR) was 33.3% among 54 evaluable patients. In the intention-to-treat analysis, median TTP was 4.6 months (95% confidential interval [CI]: 3.6-5.6 months) and median overall survival (OS) was 8.6 months (95% CI: 7.3-9.9 months). In univariate analyses, plasma vascular endothelial growth factor (VEGF) levels were correlated with clinical outcome. In patients with low (≤12.6 pg/ml) and high (>12.6 pg/ml) baseline plasma VEGF levels, RR values were 55.0% and 5.3%, respectively (P = 0.001); median TTP values were 6.9 months and 2.8 months, respectively (P = 0.0005); and median OS values were 12 months and 5 months, respectively (P <0.0001). None of these patients exhibited KRAS, BRAF, or PIK3CA mutations.
conclusionsCombination therapy comprising cetuximab and mFOLFIRI was well tolerated and active as a second-line treatment for patients with metastatic gastric cancer. Patients with low baseline plasma VEGF levels were associated with better clinical outcomes.
trial registrationClinicalTrials.gov. NCT00699881 . Registered 17 June 2008 (retrospectively registered).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.